



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 24 2005

Page 1 of 1

JRV  
fileCOPY  
Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

OFFICE OF PETITIONS

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/743,647	Menlas Pangalos	J0205/7000

John R Van Amsterdam  
Wolf Greenfield & Sacks  
600 Alantic Avenue  
Boston, MA 02210



File Folder	Initials
ECB 12/25/02	<input checked="" type="checkbox"/>
Docket Entry	<input checked="" type="checkbox"/>
Docket Cross Off	<input checked="" type="checkbox"/>
Order Copies	<input type="checkbox"/>
Annuities	<input type="checkbox"/>
Confirmation	<input type="checkbox"/>


INTERNATIONAL APPLICATION NO.	
PCT/GB99/02241	
I.A. FILING DATE	PRIORITY DATE
07/14/1999	07/14/1998

CONFIRMATION NO. 6077

371  
ABANDONMENT/TERMINATION  
LETTER



\*OC000000009152936\*



Date Mailed: 11/25/2002

## NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as an Elected Office (37 CFR 1.495), has made the following determination:

- Applicant has failed to respond to the notification of MISSING REQUIREMENTS, mailed 04/06/2001 within the time period set therein.


Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 3 - OFFICE COPY

FORM PCT/DO/EO/909 (371 Abandonment Notice)



DOCKET NO: J0205.70000US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pangalos et al.

Serial No.: 09/743,647

Filing Date: January 12, 2001

For: CLONING AND CHARACTERISATION OF NOVEL MAMMALIAN  
PEPTIDASE

RECEIVED

MAR 24 2005


Examiner: Unknown

Art Unit: Unknown

OFFICE OF PETITIONS

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 18<sup>th</sup> day of March, 2005.

  
June Watson

**Mail Stop PETITION**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir/Madam:

Transmitted herewith are the following documents:


- ☒ Copy of Notice of Abandonment mailed November 25, 2002
- ☒ Petition for Revival of an Application for Patent Abandoned Unintentionally Under 37 C.F.R. §1.137(b)
- ☒ Sequence Listing (paper copy and Computer Readable Diskette)
- ☒ Statement under 37 C.F.R. §1.821(f)
- ☒ Copy of documents as filed on June 29, 2001 for Response to Notice to File Missing Parts
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

A check in the amount of **\$1,500.00** is enclosed to cover the Petition to Revive filing fee. Please charge any underpayment or credit any overpayment to Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,  
*Pangalos, et al., Applicant*

By:

  
John R. Van Amsterdam, Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210  
Telephone: (617) 646-8000

Docket No.: J0205.70000US00

Date: March 18, 2005

xNDDx



RECEIVED  
MAR 24 2005  
OFFICE OF PETITIONS

COPY

Serial No. 09/743,647 File No. 10205/1000 By: JEN  
Title: CLONING AND CHARACTERIZATION OF NOVEL MAMMALIAN PEPTIDES  
Application of: Pamalos et al. WGS Date: 9-6-01  
The U.S. PTO Mail Room acknowledges receipt of the following on the date stamped hereon:  
☐ Mailing by Express Mail (37 CFR 1.10)  
☐ Express Mail Label No. \_\_\_\_\_  
☐ Patent Application  
    ☐ Non-provisional ☐ Provisional  
    Incl. \_\_\_\_\_ pages, ( \_\_\_\_\_ pgs) Specification, \_\_\_\_\_ # claims  
☐ Design Patent Application  
    ( \_\_\_\_\_ pgs) Abstract, ( \_\_\_\_\_ pgs) Claims \_\_\_\_\_ # claims  
☒ Declaration(s)  
    Drawings \_\_\_\_\_ Sheet(s) (FIGS. \_\_\_\_\_)  
    ☐ Formal ☐ Informal ☒ Correction  
    ☐ Utility Patent Application Transmittal of figure 2  
    ☐ Fee calculation sheet (x2)  
    ☐ CPA Transmittal  
    ☐ Verified Statement claiming small entity status  
**526 REC'd PCT/PTO 02 JUL 2001**  
☒ Other Sequence listing - paper copy & identical cdf  
Statement under 37 CFR 1.821(f)  
Copy of Not. of Missing Refs. & Not. to Comply w/ Seq.  
19E12  
DATE MAILED June 29, 2001 Ref's \_\_\_\_\_

**COPY**

Applicants: Pangalos et al.

Title: **CLONING AND  
CHARACTERIZATION OF NOVEL  
MAMMALIAN PEPTIDASES**


Date Recorded: June 29, 2001

Operating Sys.: Windows 98

Reference No.: J0205/7000

Serial Number: 09/743,647

Filing Date: January 12, 2001



Attorney's Docket No: J0205/7000


IN THE UNITED STATES PATENT & TRADEMARK OFFICE

**COPY**

Applicant(s) : Pangalos et al.  
U.S. Serial No. : 09/743,647  
U.S. Filing Date : January 12, 2001  
Int'l Apl. No. : PCT/GB99/02241  
Int'l Filing Date : 14 July 1999  
For : CLONING AND CHARACTERISATION OF NOVEL  
MAMMALIAN PEPTIDASES

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Box PCT, Commissioner for Patents, Washington, D.C. 20231, on the 29th day of June, 2001.

  
\_\_\_\_\_  
Monica E. Zombori

Box PCT  
Commissioner for Patents  
Washington, DC 20231

Sir:


Transmitted herewith are the following documents:

- ☒ Second Preliminary Amendment
- ☒ Petition for One Month Extension of Time
- ☒ Sequence Listing - paper copy and identical computer readable diskette
- ☒ Statement Under 37 CFR 1.821(f)
- ☒ Corrected drawing (1)
- ☒ Copy of Notification of Missing Requirements
- ☒ Copy of Notice to Comply with Sequence Requirements
- ☒ International Preliminary Examination Report (IPER)
- ☒ Check in the amount of \$110.00
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

If the amount of the enclosed check is considered insufficient, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

  
\_\_\_\_\_  
Helen C. Lockhart, Reg No. 39,248  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
Tel. (617) 720-3500

Attorney's Docket No.: J0205/7000  
Date: June 29, 2001  
x07/06/01



UNITED STATES PATENT AND TRADEMARK OFFICE

APR 11 2001

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NO.

09/743647

FIRST NAMED APPLICANT

PANGALOS

ATTY. DOCKET NO.

M

J0205/7000

INTERNATIONAL APPLICATION NO.

PCT/GB99/02241

I.A. FILING DATE

14 JUL 99

PRIORITY DATE

14 JUL 98

JOHN R VAN AMSTERDAM  
WOLF GREENFIELD & SACKS  
600 ATLANTIC AVENUE  
BOSTON, MA 02210

File Folder	<input checked="" type="checkbox"/>
ECB	<input checked="" type="checkbox"/>
Docket Entry	<input checked="" type="checkbox"/>
Docket Cross Off	<input checked="" type="checkbox"/>
Order Copies	<input checked="" type="checkbox"/>
Annuites	<input checked="" type="checkbox"/>
Confirmation	<input checked="" type="checkbox"/>

DATE MAILED: 06 APR 2001

**NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☐ a Designated Office (37 CFR 1.494) ☒ an Elected Office (37 CFR 1.495):
- ☒ U.S. Basic National Fee.
  - ☒ Copy of the international application.
  - ☒ Oath or Declaration of inventors(s).
  - ☐ Copy of Article 19 amendments.
  - ☐ Priority Document.
  - ☐ The International Preliminary Examination Report in English and its Annexes, if any.
  - ☐ Translation of Annexes to the International Preliminary Examination Report into English.
  - ☐ Indication of Small Entity Status.
  - ☐ Translation of the international application into English.
  - ☐ Translation of Article 19 amendments into English.
  - ☐ Other:
2. ☐ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.
- ☐ U.S. Basic National Fee.
  - ☐ Copy of the international application.
3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:
- ☐ a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
  - ☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
  - ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
  - ☐ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
  - ☐ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
  - ☐ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).
4. Additional claim fees of \$ \_\_\_\_\_ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.
5. ☒ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

**ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

**A copy of this notice MUST be returned with this response.**

Enclosed: ☐ PCT/DO/EO/917☐ Notice of Defective Translation



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

COPY

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/743647	PANGALOS	M J0205/7000
INTERNATIONAL APPLICATION NO.		
PCT/GB99/02241		
I.A. FILING DATE		PRIORITY DATE
14 JUL 99		14 JUL 98

JOHN R VAN AMSTERDAM  
WOLF GREENFIELD & SACKS  
600 ALANTIC AVENUE  
BOSTON, MA 02210

DATE MAILED: 06 APR 2001

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☐ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☐ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: \_\_\_\_\_

**APPLICANT MUST PROVIDE:**

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☐ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE  
CALL:

(703) 308-4216, for Rules interpretation,  
(703) 308-4212, for CRF submission help,  
(703) 287-0200, for PatentIn software help.

Barbara A. Campbell